The recent introduction of recombinant PTH in clinical practice for the treatment of adult patients with hypoparathyroidism (162) may help a subset of APECED patients with hypoparathyroidism to achieve optimal calcium homeostasis, particularly in the setting of pre-existing renal impairment and/or intestinal malabsorption. This evidence concerns the gene PTH and hypoparathyroidism.